Achieving best practice management of primary biliary cholangitis, now and in the future
After watching this activity, participants should be better able to:
- Describe the recommendations for diagnosis and management of patients with primary biliary cholangitis
- Evaluate emerging treatment options for patients with primary biliary cholangitis
- Review and implement individualized management for patients with primary biliary cholangitis
Professor Gideon Hirschfield and Dr Palak Trivedi engage in conversation about current best practice in the treatment and management of primary biliary cholangitis, and the potential for emerging therapies and personalization of patient care to improve patient outcomes in the future.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of gastroenterologists and hepatologists involved in the management of patients with primary biliary cholangitis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Professor Gideon Hirschfield discloses: Consultancy fees from CymaBay Therapeutics, Escient Pharmaceuticals, Gilead Sciences, GSK, HighTide Therapeutics, Intercept Pharmaceuticals, Inc., Ipsen, Mirum and Pliant Therapeutics.
Dr Palak Trivedi discloses: Advisory board fees from CymaBay Therapeutics, Dr. Falk Pharma and Ipsen. Grants/research support from ADVANZ PHARMA and GSK. Speaker’s bureau fees from ADVANZ PHARMA and Dr. Falk Pharma.
Nyingi M. Kemmer, MD, MPH, MSc has no relevant financial relationships to disclose.
Touch Medical Directors
Anne Nunn and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 15 December 2022. Dates credits expire: 15 December 2024.
If you have any questions regarding credit please contact firstname.lastname@example.org
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Addressing challenges in diagnosis and treatment of IgG4-related gastrointestinal diseaseThis activity is CE/CME accredited
Achieving best practice management of primary biliary cholangitis, now and in the futureThis activity is CE/CME accredited
Arjan Bredenoord, UEG Week 2022: Analysis of the LIBERTY-EoE-TREET study of dupilumab in eosinophilic esophagitis
Emanuel Della Torre, EASL ILC 2021: IgG4-related Systemic Disease Treatment
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out